Aging & Disease Reports Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia
The COVID-19 pandemic has the global medical profession working around the clock looking for vaccines and therapies.
The journal Aging & Disease has recently reported on a study that has proven transplantation of mesenchymal stem cells has improved the outcome of 7 patients diagnosed with COVID-19 Pneumonia in Bejing, China. Celltex is continuing to monitor this effective research.
If you currently have your MSCs banked at Celltex and are wondering what options are available to you, please contact the Client Services team today by completing the form on our Request a Consultation page, by calling (713) 590-1000 or sending an email to email@example.com. If you are not a client but would like to bank your MSCs, please complete our online client assessment and a Client Services Coordinator will contact you.
More Recent News
Celltex Therapeutics Receives Another FDA Approval: Phase II Clinical Trial Using Mesenchymal Stem Cells (MSCs) as a Prophylactic Against COVID-19Read More
Rick Perry Discusses Celltex’s COVID-19 Clinical Trials on Fox News TV
Former U.S. Secretary of Energy and former Governor of Texas, Rick Perry, was on Fox News TV discussing Celltex’s COVID-19 ongoing clinical trials and the ingenuity that will deliver a victory over this virus.Read More